Melanotan-I
Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647
A synthetic analog of alpha-melanocyte-stimulating hormone that stimulates melanogenesis, increasing skin pigmentation and providing photoprotection against UV radiation.
Completed
PHASE1
NCT00345670
Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children
MedImmune LLC
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04392154
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT01225562
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
AstraZeneca
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
NA
NCT03811769
Large Stroke Therapy Evaluation
University Hospital, Montpellier
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE1, PHASE2
NCT01896999
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT02193282
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT02595944
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT04989504
Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy
Alliance for Clinical Trials in Oncology
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
NA
NCT02194738
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT00333840
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Novartis Pharmaceuticals
INTERVENTIONAL
Updated Dec 15, 2025
Withdrawn
PHASE2
NCT01714089
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
Revalesio Corporation
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT01853748
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Dana-Farber Cancer Institute
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT00043511
Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT00063999
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
GOG Foundation
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NCT00900484
SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
OBSERVATIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT01696058
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
Boehringer Ingelheim
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00859534
Phase II Solar Urticaria (SU) Pilot Study
Clinuvel Pharmaceuticals Limited
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT03701282
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT04181060
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE3
NCT00133224
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
Cell Genesys
INTERVENTIONAL
Updated Dec 15, 2025